Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Cullinan Therapeutics is providing a same-day webcast and replay for investors on interim Phase 3 REZILIENT3 zipalertinib data.

Rhea-AI Summary

Cullinan Therapeutics (CGEM) will host a virtual event on Sept. 14, 2026 at 8:00 a.m. ET for analysts and institutional investors to discuss results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy, which were presented at the IASLC 2026 World Conference on Lung Cancer.

A live webcast and subsequent replay will be available via the events page of Cullinan Therapeutics’ investor relations website.

Key Terms

interim analysis, phase 3, t cell engagers

3 terms

interim analysis medical

"results from the planned interim analysis of the Phase 3 REZILIENT3 trial"

An interim analysis is an early review of a project or process before it is fully completed. For investors, it provides a snapshot of progress or performance, helping to identify whether things are on track, need adjustment, or should be stopped early. Think of it as a progress report that can influence decisions before the final outcome is known.

phase 3 medical

"the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

t cell engagers technical

"developing potential first- or best-in-class, disease-modifying T cell engagers"

T cell engagers are engineered molecules that act like a matchmaker or bridge, linking a patient’s T cells (immune cells that kill infected or cancerous cells) directly to diseased cells so the immune system can destroy them. For investors, they matter because successful T cell engagers can become high-value therapies with steep clinical and regulatory milestones that drive a biotech company’s revenue potential and share price, while failures or safety issues can rapidly reduce valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host a virtual event today at 8:00 a.m. ET

CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET to discuss the results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy presented in Presidential Symposium 2 at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Virtual Event Details

Cullinan Therapeutics will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET. Participants from Cullinan Therapeutics include Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, MD, MBA, Chief Medical Officer.

A live webcast will be available via the events page of Cullinan Therapeutics’ investor relations website at https://investors.cullinantherapeutics.com/events. A replay will be archived on the website following the event.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

Contacts

Cullinan Therapeutics
Investors
Nick Smith
+1 401.241.3516
Nsmith@cullinantx.com

Media
Rose Weldon
+1 215.801.7644
Rweldon@cullinantx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can investors and analysts access Cullinan Therapeutics’ virtual event and replay?

A live webcast of the 8:00 a.m. ET virtual event will be available via the events page of Cullinan Therapeutics’ investor relations website at https://investors.cullinantherapeutics.com/events, and a replay will be archived on the same website following the event.